ES2655505T3 - Producto y procedimiento para el tratamiento de la diarrea - Google Patents
Producto y procedimiento para el tratamiento de la diarrea Download PDFInfo
- Publication number
- ES2655505T3 ES2655505T3 ES14722445.5T ES14722445T ES2655505T3 ES 2655505 T3 ES2655505 T3 ES 2655505T3 ES 14722445 T ES14722445 T ES 14722445T ES 2655505 T3 ES2655505 T3 ES 2655505T3
- Authority
- ES
- Spain
- Prior art keywords
- treatment
- patients
- diarrhea
- group
- procedure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 206010012735 Diarrhoea Diseases 0.000 title abstract description 6
- 238000000034 method Methods 0.000 title description 2
- ZKLPARSLTMPFCP-UHFFFAOYSA-N Cetirizine Chemical compound C1CN(CCOCC(=O)O)CCN1C(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-UHFFFAOYSA-N 0.000 abstract description 2
- 229960001803 cetirizine Drugs 0.000 abstract description 2
- 239000000938 histamine H1 antagonist Substances 0.000 abstract 2
- ZKLPARSLTMPFCP-OAQYLSRUSA-N 2-[2-[4-[(R)-(4-chlorophenyl)-phenylmethyl]-1-piperazinyl]ethoxy]acetic acid Chemical compound C1CN(CCOCC(=O)O)CCN1[C@@H](C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-OAQYLSRUSA-N 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 239000003485 histamine H2 receptor antagonist Substances 0.000 abstract 1
- 229960001508 levocetirizine Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000000902 placebo Substances 0.000 description 7
- 229940068196 placebo Drugs 0.000 description 7
- 208000019902 chronic diarrheal disease Diseases 0.000 description 3
- 208000001647 Renal Insufficiency Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
- AXRYRYVKAWYZBR-UHFFFAOYSA-N Atazanavir Natural products C=1C=C(C=2N=CC=CC=2)C=CC=1CN(NC(=O)C(NC(=O)OC)C(C)(C)C)CC(O)C(NC(=O)C(NC(=O)OC)C(C)(C)C)CC1=CC=CC=C1 AXRYRYVKAWYZBR-UHFFFAOYSA-N 0.000 description 1
- 108010019625 Atazanavir Sulfate Proteins 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 206010056979 Colitis microscopic Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 241000224466 Giardia Species 0.000 description 1
- 102000003834 Histamine H1 Receptors Human genes 0.000 description 1
- 108090000110 Histamine H1 Receptors Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229940125714 antidiarrheal agent Drugs 0.000 description 1
- 239000003793 antidiarrheal agent Substances 0.000 description 1
- AXRYRYVKAWYZBR-GASGPIRDSA-N atazanavir Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)[C@@H](O)CN(CC=1C=CC(=CC=1)C=1N=CC=CC=1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C1=CC=CC=C1 AXRYRYVKAWYZBR-GASGPIRDSA-N 0.000 description 1
- 229960003277 atazanavir Drugs 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 208000008609 collagenous colitis Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229960001596 famotidine Drugs 0.000 description 1
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 1
- 229940077716 histamine h2 receptor antagonists for peptic ulcer and gord Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229960004130 itraconazole Drugs 0.000 description 1
- 229960004125 ketoconazole Drugs 0.000 description 1
- 208000004341 lymphocytic colitis Diseases 0.000 description 1
- 208000008275 microscopic colitis Diseases 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361782608P | 2013-03-14 | 2013-03-14 | |
| US201361782608P | 2013-03-14 | ||
| PCT/US2014/027323 WO2014152420A2 (en) | 2013-03-14 | 2014-03-14 | Product and method for treating diarrhea |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2655505T3 true ES2655505T3 (es) | 2018-02-20 |
Family
ID=50680150
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES14722445.5T Active ES2655505T3 (es) | 2013-03-14 | 2014-03-14 | Producto y procedimiento para el tratamiento de la diarrea |
| ES17189072T Active ES2743604T3 (es) | 2013-03-14 | 2014-03-14 | Producto y procedimiento para el tratamiento de la diarrea |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES17189072T Active ES2743604T3 (es) | 2013-03-14 | 2014-03-14 | Producto y procedimiento para el tratamiento de la diarrea |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US9717726B2 (enExample) |
| EP (3) | EP3269364B1 (enExample) |
| JP (4) | JP6313417B2 (enExample) |
| KR (4) | KR20180088514A (enExample) |
| CN (2) | CN108939076A (enExample) |
| AU (3) | AU2014239878B2 (enExample) |
| BR (2) | BR122017004716A2 (enExample) |
| CA (1) | CA2906005C (enExample) |
| DK (1) | DK2968205T3 (enExample) |
| ES (2) | ES2655505T3 (enExample) |
| HK (1) | HK1247557B (enExample) |
| HU (1) | HUE035201T2 (enExample) |
| IL (3) | IL273377B2 (enExample) |
| MX (2) | MX366329B (enExample) |
| MY (1) | MY175326A (enExample) |
| PL (1) | PL2968205T3 (enExample) |
| PT (1) | PT2968205T (enExample) |
| RU (1) | RU2015143475A (enExample) |
| WO (1) | WO2014152420A2 (enExample) |
| ZA (1) | ZA201708539B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9717726B2 (en) | 2013-03-14 | 2017-08-01 | Maregade Rx, LLC | Product and method for treating diarrhea |
| US20150132410A1 (en) * | 2013-11-14 | 2015-05-14 | Michael M. Jacobs | Compositions and methods for the prevention and treatment of alcohol-induced hangover syndrome |
| US20180185356A1 (en) * | 2016-12-23 | 2018-07-05 | Maregade Rx, LLC | Low dose product and method for treating diarrhea |
| IT201900012645A1 (it) * | 2019-07-23 | 2021-01-23 | Eros Zanotti | Una composizione farmaceutica per l'uso nel trattamento delle chinetosi |
| CN112616320B (zh) * | 2019-08-05 | 2024-04-05 | 株式会社日立高新技术 | 等离子处理装置 |
| CN115515435A (zh) * | 2020-02-11 | 2022-12-23 | 沃尔夫森医疗中心 | 有效治疗溃疡性结肠炎的方法 |
| CN117280446A (zh) | 2021-08-23 | 2023-12-22 | 株式会社日立高新技术 | 等离子处理装置以及等离子处理方法 |
| WO2023049205A1 (en) | 2021-09-22 | 2023-03-30 | Hista Rx Llc | Compositions and methods for treating and preventing interstitial cystitis |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5204118A (en) | 1989-11-02 | 1993-04-20 | Mcneil-Ppc, Inc. | Pharmaceutical compositions and methods for treating the symptoms of overindulgence |
| US5096894A (en) * | 1990-04-03 | 1992-03-17 | Bristol-Myers Squibb Company | Rice dextrin oral rehydration solution |
| AU7255094A (en) | 1993-07-06 | 1995-02-06 | Mcneil-Ppc, Inc. | H2 antagonist-antihistamine combinations |
| US6264984B1 (en) * | 1999-12-06 | 2001-07-24 | Bristol-Myers Squibb Company | Effervescent histamine H2 antagonist composition |
| US6656492B2 (en) * | 2000-06-30 | 2003-12-02 | Yamanouchi Pharmaceutical Co., Ltd. | Quick disintegrating tablet in buccal cavity and manufacturing method thereof |
| CA2430292A1 (en) | 2000-11-30 | 2002-06-06 | The Bio Balance Corp. | Preparation of compositions comprising bacterial strains and volatile plant extracts and therapeutic and industrial applications thereof |
| WO2003044023A1 (en) * | 2001-11-23 | 2003-05-30 | Janssen Pharmaceutica N.V. | The use of anti-histaminics for acute reduction of elevated intracranial pressure |
| SE528789C2 (sv) | 2004-09-10 | 2007-02-13 | Sandvik Intellectual Property | PVD-belagt skär av hårdmetall samt sätt att tillverka detta |
| US20070077300A1 (en) * | 2005-09-30 | 2007-04-05 | Wynn David W | Oral compositions containing a salivation inducing agent |
| US20090312358A1 (en) | 2006-03-22 | 2009-12-17 | Trustees Of Boston University | Method for management of diarrhea |
| US8207188B2 (en) | 2006-04-07 | 2012-06-26 | Michalis Nicolaou | Treatment of diseases modulated by a H4 receptor agonist |
| US8207292B2 (en) | 2007-02-12 | 2012-06-26 | Michalis Nicolaou | Treatment of COPD, gastro-esophageal reflux disease (GERD), food allergies and other gastrointestinal conditions and disorders ameliorated by proper histamine management using a combination of histidine decarboxylase inhibitors, LRA drugs, anti-H1 and/or anti-H2 drugs |
| US20070254050A1 (en) * | 2006-05-01 | 2007-11-01 | Quart Barry D | Method for treatment of diarrhea-predominant irritable bowel syndrome |
| US20090042972A1 (en) * | 2006-05-19 | 2009-02-12 | Somaxon Pharmaceuticals, Inc. | Methods of using low-dose doxepin for the improvement of sleep |
| CA2721133C (en) * | 2007-04-13 | 2018-11-06 | Somaxon Pharmaceuticals, Inc. | Low-dose doxepin formulations and methods of making and using the same |
| US8263581B2 (en) | 2009-07-03 | 2012-09-11 | Jdp Therapeutics, Inc. | Non-sedating antihistamine injection formulations and methods of use thereof |
| EP3415627A1 (en) | 2012-11-13 | 2018-12-19 | Codiak BioSciences, Inc. | Delivery of therapeutic agent |
| US9717726B2 (en) | 2013-03-14 | 2017-08-01 | Maregade Rx, LLC | Product and method for treating diarrhea |
| US20180185356A1 (en) | 2016-12-23 | 2018-07-05 | Maregade Rx, LLC | Low dose product and method for treating diarrhea |
-
2014
- 2014-03-13 US US14/209,937 patent/US9717726B2/en active Active
- 2014-03-14 KR KR1020187021688A patent/KR20180088514A/ko not_active Ceased
- 2014-03-14 EP EP17189072.6A patent/EP3269364B1/en active Active
- 2014-03-14 HU HUE14722445A patent/HUE035201T2/hu unknown
- 2014-03-14 KR KR1020207023569A patent/KR20200100211A/ko not_active Ceased
- 2014-03-14 JP JP2016502404A patent/JP6313417B2/ja active Active
- 2014-03-14 MY MYPI2015703092A patent/MY175326A/en unknown
- 2014-03-14 RU RU2015143475A patent/RU2015143475A/ru not_active Application Discontinuation
- 2014-03-14 CN CN201810755897.7A patent/CN108939076A/zh active Pending
- 2014-03-14 BR BR122017004716-7A patent/BR122017004716A2/pt not_active Application Discontinuation
- 2014-03-14 CA CA2906005A patent/CA2906005C/en active Active
- 2014-03-14 IL IL273377A patent/IL273377B2/en unknown
- 2014-03-14 WO PCT/US2014/027323 patent/WO2014152420A2/en not_active Ceased
- 2014-03-14 KR KR1020217004881A patent/KR102449977B1/ko active Active
- 2014-03-14 EP EP14722445.5A patent/EP2968205B1/en active Active
- 2014-03-14 MX MX2017011532A patent/MX366329B/es unknown
- 2014-03-14 BR BR112015022513A patent/BR112015022513A2/pt not_active Application Discontinuation
- 2014-03-14 KR KR1020157029028A patent/KR101884506B1/ko active Active
- 2014-03-14 AU AU2014239878A patent/AU2014239878B2/en active Active
- 2014-03-14 DK DK14722445.5T patent/DK2968205T3/da active
- 2014-03-14 CN CN201480022471.0A patent/CN105324112B/zh active Active
- 2014-03-14 PT PT147224455T patent/PT2968205T/pt unknown
- 2014-03-14 EP EP19169633.5A patent/EP3581205A3/en active Pending
- 2014-03-14 PL PL14722445T patent/PL2968205T3/pl unknown
- 2014-03-14 MX MX2015011885A patent/MX350814B/es active IP Right Grant
- 2014-03-14 ES ES14722445.5T patent/ES2655505T3/es active Active
- 2014-03-14 ES ES17189072T patent/ES2743604T3/es active Active
-
2015
- 2015-09-09 IL IL241372A patent/IL241372B/en active IP Right Grant
-
2016
- 2016-09-06 US US15/257,674 patent/US10034875B2/en active Active
-
2017
- 2017-10-24 AU AU2017251701A patent/AU2017251701B2/en active Active
- 2017-12-13 IL IL256300A patent/IL256300B/en active IP Right Grant
- 2017-12-15 ZA ZA2017/08539A patent/ZA201708539B/en unknown
-
2018
- 2018-03-22 JP JP2018054088A patent/JP6473254B2/ja active Active
- 2018-05-28 HK HK18106976.5A patent/HK1247557B/en unknown
- 2018-07-06 US US16/029,384 patent/US11058681B2/en active Active
-
2019
- 2019-01-24 JP JP2019009896A patent/JP6790140B2/ja active Active
- 2019-02-28 AU AU2019201412A patent/AU2019201412A1/en not_active Abandoned
-
2020
- 2020-11-04 JP JP2020184294A patent/JP2021046400A/ja active Pending
-
2021
- 2021-05-28 US US17/333,525 patent/US20220047583A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dimopoulos et al. | Carfilzomib, lenalidomide, and dexamethasone in patients with relapsed multiple myeloma categorised by age: secondary analysis from the phase 3 ASPIRE study | |
| Villanueva et al. | β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial | |
| Lataillade et al. | Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study | |
| Brose et al. | Vemurafenib in patients with BRAFV600E-positive metastatic or unresectable papillary thyroid cancer refractory to radioactive iodine: a non-randomised, multicentre, open-label, phase 2 trial | |
| Perl et al. | Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study | |
| Muthuri et al. | Effectiveness of neuraminidase inhibitors in reducing mortality in patients admitted to hospital with influenza A H1N1pdm09 virus infection: a meta-analysis of individual participant data | |
| Yahata et al. | Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin | |
| Koopman et al. | Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial | |
| CR20230330A (es) | Agonistas del receptor gpcr, composiciones farmaceuticas que los comprenden y métodos para su uso | |
| Imazio et al. | Efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2): a multicentre, double-blind, placebo-controlled, randomised trial | |
| US8697662B2 (en) | Methods for treating Kaposi sarcoma | |
| Jain et al. | Anaphylaxis following intravenous paracetamol: the problem is the solution | |
| ES2743604T3 (es) | Producto y procedimiento para el tratamiento de la diarrea | |
| Mallet et al. | Major depressive disorder (MDD) and schizophrenia–Addressing unmet needs with partial agonists at the D2 receptor: A review | |
| Mateos et al. | Modification of belantamab mafodotin dosing to balance efficacy and tolerability in the DREAMM-7 and DREAMM-8 trials | |
| Capetti et al. | Dolutegravir plus rilpivirine dual therapy in treating HIV-1 infection | |
| Arends et al. | Induction therapy with short-term high-dose intravenous cyclophosphamide followed by mycophenolate mofetil in proliferative lupus nephritis | |
| Raedler | Akynzeo (Netupitant and Palonosetron), a dual-acting oral agent, approved by the FDA for the prevention of chemotherapy-induced nausea and vomiting | |
| Wheelden et al. | A novel adverse event associated with olaparib therapy in a patient with metastatic breast cancer | |
| Mave et al. | Tuberculosis disease among people with HIV: therapeutic advances | |
| VanCleave et al. | Probable metronidazole induced serum sickness-like reaction in a paediatric patient. | |
| Kwekwesa et al. | Breast enlargement in Malawian males on the standard first-line antiretroviral therapy regimen: Case reports and review of the literature | |
| Aurilio | Tapentadol prolonged release in fragile geriatric patients> 70 years with chronic severe musculoskeletal pain: an open-label, prospective, observational study | |
| Lee et al. | Modern-Era Challenges in the Clinical Management of Graft-Versus-Host Disease | |
| Cada et al. | Netupitant/palonosetron |